

27 November 2017

ASX Announcement

Market Announcement – 2017 Annual General Meeting Chairman Opening Address

Enclosed is a copy of the Opening Address, to be presented by Peter Coolentianos (Chair of IQ3Corp Limited), at 11:15am on 27th November 2017, at the IQ3Corp Limited Annual General Meeting to be held at the Grace Hotel, Sydney.



Gerardo Incollingo
Company Secretary

iQ3

Translating science into capital and beyond

iQ3Corp. is the world's first dedicated life science corporate finance and advisory firm.

Chairman's Opening Address

The iQ3Corp team has continued to successfully set the groundwork to implement the company's strategy and objectives. We have continued to invest in the development of the company's distribution base across Australia and the USA, building the company's profile in the Life Science Industry and positioning the company in the capital markets.

Revenue in FY17 was \$5.9m compared to \$2.1m in the prior corresponding period, reflecting our continued expansion of activity in specialist life science corporate advisory activities in FY17.

The net loss, after tax of the group for the year ended 30 June 2017, was \$49,595 (2016: \$1,987,751), which represents a substantial improvement from last year, continuing the expenditure required for investing in the required infrastructure to execute the Company's strategy. The improvement in the accounts can be identified from the general growing opportunities that Life Science projects are creating in Australia. IQ3's specialized skills allowed us to capitalise on these opportunities. These industry opportunities including the acquisition and licensing of life science assets for new and existing clients, generated greater levels of corporate advisory work for iQ3Corp which was reflected in the company's improved cashflow and made evident in the improved Profit & Loss result for the year as disclosed in the accounts.

During the year we welcomed Gerardo Incollingo as our new secretary replacing Kelvin Boateng.

Finally, I would like to thank my fellow board of directors and their executive management team for the continuing commitment and professionalism they have displayed during the year. Without this dedicated team of individuals, we could not deliver the core mandate of making a difference in the Australian Life Science sector by giving it access to capital markets in Australia and giving this sector, the opportunity to capitalise on its ability to become a major global force internationally.